GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (XSWX:OBSN) » Definitions » Capital Expenditure

ObsEva (XSWX:OBSN) Capital Expenditure : CHF-0.02 Mil (TTM As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is ObsEva Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

ObsEva's cash flow for capital expenditures for the three months ended in Dec. 2022 was CHF0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2022 was CHF-0.02 Mil.

ObsEva Capital Expenditure Historical Data

The historical data trend for ObsEva's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Capital Expenditure Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -0.19 -4.96 - -0.01 -

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.01 - -

ObsEva Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ObsEva (XSWX:OBSN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (XSWX:OBSN) » Definitions » Capital Expenditure
Comparable Companies
XSWX:ADXN XSWX:SPEX XSWX:KNRS XSWX:EVE XSWX:RLF OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270
Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
Website
https://www.obseva.com
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (XSWX:OBSN) Headlines

No Headlines